News - Page 132 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article PsyBio Therapeutics Successfully Completes First Pre-IND Meeting with the United States Food and Drug Administration

PsyBio Therapeutics Successfully Completes First Pre-IND Meeting with the United States Food and Drug Administration

Post published:December 7, 2021
Post category:Press Release

Read more about the article Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA) to Advance Research on Non-Hallucinogenic Therapies to Treat Substance Use Disorders

Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA) to Advance Research on Non-Hallucinogenic Therapies to Treat Substance Use Disorders

Post published:December 7, 2021
Post category:Press Release

Read more about the article Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic from In Vivo Behavioral Studies

Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic from In Vivo Behavioral Studies

Post published:December 7, 2021
Post category:Press Release

Read more about the article Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Post published:December 6, 2021
Post category:Press Release

Read more about the article Psychedelic Bulletin: MAPS’ $70m Investment Vehicle; atai’s Increased Stake in COMPASS; SSRI Psilocybin Interaction Study

Psychedelic Bulletin: MAPS’ $70m Investment Vehicle; atai’s Increased Stake in COMPASS; SSRI Psilocybin Interaction Study

Post published:December 5, 2021
Post category:Psychedelic Bulletin

Read more about the article Michael Falvey joins COMPASS Pathways as Chief Financial Officer

Michael Falvey joins COMPASS Pathways as Chief Financial Officer

Post published:December 4, 2021
Post category:Press Release

Read more about the article Silo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide

Silo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide

Post published:December 2, 2021
Post category:Press Release

Read more about the article Psychiatrist and Addiction Researcher, Dr. Henry Kranzler Joins Entheon Advisory Board

Psychiatrist and Addiction Researcher, Dr. Henry Kranzler Joins Entheon Advisory Board

Post published:December 1, 2021
Post category:Press Release

Read more about the article Psyched Wellness Presents AME-1 to Health Canada in Pre-Submission Meeting

Psyched Wellness Presents AME-1 to Health Canada in Pre-Submission Meeting

Post published:December 1, 2021
Post category:Press Release

Read more about the article COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

Post published:December 1, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.